The Searle Company Limited

KASE:SEARL Stock Report

Market Cap: PK₨42.2b

Searle Valuation

Is SEARL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SEARL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SEARL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SEARL's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEARL?

Key metric: As SEARL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SEARL. This is calculated by dividing SEARL's market cap by their current earnings.
What is SEARL's PE Ratio?
PE Ratio42.9x
EarningsPK₨983.31m
Market CapPK₨42.17b

Price to Earnings Ratio vs Peers

How does SEARL's PE Ratio compare to its peers?

The above table shows the PE ratio for SEARL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19x
HINOON Highnoon Laboratories
16.2xn/aPK₨49.0b
AGP AGP
23.1xn/aPK₨47.8b
HPL Hoechst Pakistan
15.5xn/aPK₨25.1b
ABOT Abbott Laboratories (Pakistan)
21.2xn/aPK₨106.2b
SEARL Searle
42.9xn/aPK₨42.2b

Price-To-Earnings vs Peers: SEARL is expensive based on its Price-To-Earnings Ratio (42.9x) compared to the peer average (19x).


Price to Earnings Ratio vs Industry

How does SEARL's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

13 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SEARL 42.9xIndustry Avg. 24.7xNo. of Companies74PE020406080100+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SEARL is expensive based on its Price-To-Earnings Ratio (42.9x) compared to the Asian Pharmaceuticals industry average (24.7x).


Price to Earnings Ratio vs Fair Ratio

What is SEARL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEARL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SEARL's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies